The process of TIL therapy is complex and requires the coordination of multiple specialties at authorized treatment centers, ...
Thomas Yau and colleagues’ CheckMate 9DW trial has yielded unprecedented results, with nivolumab plus ipilimumab reaching an overall response rate of 36%, a median progression-free survival of 9·1 ...
Treatments for unresectable hepatocellular carcinoma: insights from CheckMate 9DW – Authors' reply
We thank Akhil Santhosh and Nihanthy D Sreenath and Liting Zhang and colleagues for their interest in our trial. The CheckMate 9DW trial showed clinically significant overall survival benefit for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback